Boron neutron capture therapy for head and neck cancer: Relevance of nuclear-cytoplasmic volume ratio and anti-tumor effect. -A preliminary report-

被引：0

作者：

Aihara T. ^{[1
,2
]}

Hiratsuka J. ^{[3
,4
]}

Kamitani N. ^{[3
,4
]}

Nishimura H. ^{[4
]}

Ono K. ^{[1
,2
]}

机构：

[1] Kansai BNCT Medical Center and Department of Otolaryngology Head and Neck Surgery, Osaka Medical College, Takatsuki

[2] Department of Otolaryngology Head and Neck Surgery, Osaka Medical College, Takatsuki

[3] Departments of Radiation Oncology and Departments of Pathology, Kawasaki Medical School, Kurashiki

[4] Departments of Pathology, Kawasaki Medical School, Kurashiki

来源：

Applied Radiation and Isotopes | 2020年 / 163卷

基金：

日本学术振兴会;

关键词：

!sup]10[!/sup]B; ABE factor; BNCT; CBE factor; Head and neck cancer; N/C ratio;

D O I：

10.1016/j.apradiso.2020.109212

中图分类号：

学科分类号：

摘要：

BNCT is a type of particle beam radiation therapy that utilizes an α particle and 7Li nucleus generated when a thermal neutron is captured by a 10B nucleus involved in the boron compound that has been taken up into tumor tissue selectively. In this report, the relevance of N/C ratio of tumor cell and anti-tumor effect for BNCT clinical cases of head and neck cancer were verified. Examination of pre-irradiated tumor histopathological specimens of 9 BNCT treated head and neck cancer patients (4 CR patients, 5 non-CR patients) was performed. The statistically significant difference between the CR group and the non-CR group was examined for the physical dose was multiplied by the absolute biological effectiveness (ABE) value determined from the patient's tumor specific N/C ratio. Analysis showed the mean tumor dose could not distinguish between CR and non-CR groups. However, the ABE dose could clearly distinguish between the CR group and the non-CR group (p = 0.0250). The N/C ratio of tumor cell can influence the anti-tumor effect of BNCT for HNC. © 2020 Elsevier Ltd

引用

共 13 条

[1]

Aihara T., Hitatuka H., Morita N., Et al., First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA PET, Head Neck, 10, pp. 850-855, (2006)

[2]

Aihara T., Morita N., Kamitani N., Et al., BNCT for advanced or recurrent head and neck cancer, Appl. Radiat. Isot., 88, pp. 12-15, (2014)

[3]

Aihara T., Morita N., Kamitani N., Et al., Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck, Int. J. Clin. Oncol., 19, pp. 437-444, (2014)

[4]

Aihara T., Hiratsuka J., Fukumitsu N., Et al., Evaluation of fluoride-18-labeled boronophenylalanine-positron emission tomography imaging for the assessment of boron neutron capture therapy in patients with recurrent head and neck squamous cell carcinoma, Otolaryngology (Rochester), 6, (2016)

[5]

Coderre J.A., Button T.M., Micca P.L., Et al., Neutron capture therapy of the 9L rat gliosarcoma using the p-boronophenylalanine-fructose complex, Int. J. Radiat. Oncol. Biol. Phys., 30, 3, pp. 643-652, (1994)

[6]

Kankaanranta L., Seppala T., Koivunoro H., Et al., Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial, Int. J. Radiat. Oncol. Biol. Phys., 82, pp. e67-75, (2012)

[7]

Kato I., Fujita Y., Maruhashi A., Et al., Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies, Appl. Radiat. Isot., 67, pp. S37-S42, (2009)

[8]

Mishima Y., Neutron capture treatment of malignant melanoma using 10B-chlorpromazine, Pigm. Cell Res., 1, pp. 215-221, (1973)

[9]

Mishima Y., Melanoma and Nonmelanoma Neutron Capture Therapy Using Gene Therapy : Overview, Advances in Neutron Capture Therapy, vols. 10–25, (1997)

[10]

Ono K., Tanaka H., Tamari Y., Watanabe T., Suzuki M., Masunaga S., Proposal for determining absolute biological effectiveness of boron neutron capture therapy—the effect of <sup>10</sup>B(n,α)<sup>7</sup> Li dose can be predicted from the nucleocytoplasmic ratio or the cell size, –8, (2018)

← 1 2 →